The 2025 Health Tech Competition serves as a pivotal platform where the convergence of scientific rigor and clinical innovation is put under the spotlight. Health technology companies worldwide are invited to demonstrate their products and technologies designed to prevent, diagnose, or treat a range of cardiovascular conditions such as hypertension, stroke, heart failure, and other related disorders. This competition does not merely celebrate new ideas but emphasizes the viability and impact of these solutions in practical healthcare settings, focusing on tangible improvements in patient outcomes.

This year’s cohort of finalists exemplifies a remarkable diversity of technological approaches, each targeting unique aspects of cardiovascular health challenges. Brainomix, based in Oxford, England, utilizes advanced artificial intelligence (AI) algorithms to enhance stroke diagnosis precision and facilitate timely, evidence-based treatment decisions. Through their AI-powered software, they aim to reduce diagnostic ambiguity and accelerate intervention times, which are critical in stroke management where every minute counts.

Complementing this, Cambrian Health from San Francisco leverages AI to construct platforms that ensure the seamless execution of clinical best practices directly at the point of care. Their system focuses on embedding clinical workflows with decision support tools to enhance adherence to treatment protocols, thereby improving overall healthcare quality and consistency.

From Boston, Lumia introduces wearable technologies targeting patients suffering from orthostatic intolerance and chronic blood flow disorders. These wearables are engineered to provide continuous physiological monitoring, delivering real-time data and enabling dynamic patient management outside traditional clinical environments. Such devices hold promise not only in augmenting patient quality of life but also in furnishing clinicians with actionable insights for personalized treatment plans.

Noah Labs, positioned in Berlin, pioneers the transformation of voice signals into digital biomarkers, a novel approach enabling earlier detection of cardiometabolic diseases. This innovative technology harnesses subtle changes in voice patterns linked to underlying physiological and metabolic shifts, presenting a non-invasive and scalable screening method with profound implications for early intervention strategies.

PolyVascular, headquartered in Houston, Texas, is dedicated to developing minimally invasive therapeutic solutions specifically tailored for pediatric patients with congenital heart disease. By focusing on reducing the frequency of open-heart surgeries through innovative catheter-based interventions, PolyVascular aims to significantly improve long-term outcomes and quality of life for affected children.

The finalists will present their innovations live during the American Heart Association’s Scientific Sessions 2025 at the Ernest N. Morial Convention Center in New Orleans. These presentations will be critically evaluated by a distinguished panel of judges, emphasizing the validity of the prototype or product’s functioning in real-world settings, the scientific rigor underpinning the validation studies, and the overall impact on patient outcomes driven by technological innovation.

The evaluation process is meticulous, weighing evidence-based research integration and the ability of the technology to meaningfully shift clinical paradigms. The judging panel comprises a blend of seasoned academic cardiologists, clinical innovators, venture capital experts, and even media personalities extensively involved in cardiovascular advocacy. This diverse expertise ensures a comprehensive assessment reflecting scientific credibility, clinical utility, and market potential.

Aside from monetary or material awards, the winner gains entry to the Center for Health Technology & Innovation’s Innovators’ Network—a consortium designed to foster collaboration among entrepreneurs, clinicians, researchers, and payers. This network offers unprecedented opportunities to collectively overcome practical obstacles in clinical outcome studies, facilitate science-to-technology translation, and generate the robust evidence necessary for widespread clinical adoption and reimbursement success.

Moreover, members of the Innovators’ Network can leverage access to the American Heart Association’s comprehensive digital libraries, containing rigorous, evidence-based scientific guidelines and clinical recommendations essential for guiding the development of digital health technologies. This symbiosis between guideline development and technology advancement exemplifies a forward-thinking approach to healthcare innovation where regulatory and clinical pathways are intertwined.

Robert A. Harrington, M.D., FAHA, a far-reaching leader in cardiovascular medicine and past president of the American Heart Association, reflects on the competition’s broader significance. He stresses that the Center’s mission is not only to accelerate innovation but to foster an ecosystem where these solutions can be rapidly validated, scaled, and integrated into patient care effectively. Through consortium efforts, developers are empowered to tackle some of the most complex challenges in cardiovascular disease by leveraging collective insights and resources.

The Health Tech Competition and the broader Center initiatives are indispensable in addressing systemic barriers that historically delay the translation of cutting-edge research into practical therapies. As cardiovascular diseases continue to claim millions of lives annually, embracing technological innovation while maintaining rigorous scientific validation remains pivotal. This unique synergy between advanced technology, clinical expertise, and supportive networks creates a fertile environment for breakthroughs that could transform the landscape of cardiovascular health.

For those interested in following this transformative journey in cardiovascular innovation, the Health Tech Competition represents a beacon of progress and hope. The finalist showcase at Scientific Sessions 2025 promises to reveal technologies that could redefine cardiovascular diagnostics, monitoring, and treatment paradigms, propelling the field into a new era of precision and patient-centered care. Through initiatives like this, the American Heart Association exemplifies sustained leadership in driving meaningful change, catalyzing technologies that hold the promise of saving countless lives globally.

Subject of Research: Development and evaluation of innovative health technologies targeting cardiovascular and stroke patient outcomes.

Article Title: Bridging Innovation and Practice: The American Heart Association’s 2025 Health Tech Competition Finalists Unveil Next-Gen Cardiovascular Solutions

News Publication Date: November 4, 2025

Web References:

• https://ahahealthtech.org/aha-health-tech-competition-2025
• https://newsroom.heart.org/news/5-health-technology-start-ups-finalists-in-global-heart-disease-solution-competition

References:

• Circulation Journal, AHA official research (https://doi.org/10.1161/cir.0000000000001303)

Keywords: Cardiovascular innovation, heart disease, stroke, artificial intelligence, wearable health tech, digital biomarkers, pediatric cardiology, clinical adoption, health technology competition

Heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF) present distinct pathophysiological challenges. Unlike traditional heart failure where the heart’s pumping capacity is markedly diminished, HFpEF patients maintain an ejection fraction above 50%. Here, the cardiac muscle contracts adequately but exhibits impaired relaxation during diastole, leading to inefficient ventricular filling. HFmrEF, characterized by ejection fractions between 41% and 49%, occupies a nuanced space between preserved and reduced function, with clinical profiles and treatment implications that are only recently being elucidated through emerging research.

The AHA’s new three-year quality improvement initiative, named IMPLEMENT-EF, seeks to systematically dissect and address these complexities. By mapping deficiencies in the patient journey and care delivery models, the initiative strives to delineate optimal management strategies and foster consistent application of evidence-based therapies. Using robust data obtained from the AHA’s Get With The Guidelines® – Heart Failure registry, it will leverage real-world clinical insights to refine treatment paradigms and disseminate best practices across care settings nationwide.

Central to the initiative is the mobilization of multidisciplinary care teams. Recognizing that effective management of HFpEF and HFmrEF transcends conventional cardiology, the program incorporates pharmacists, nurses, and allied health professionals as integral collaborators. This team-based approach emphasizes early identification of at-risk individuals, prompt initiation of scientific, protocol-driven treatments, and ongoing patient support to ensure adherence and optimal health outcomes.

Ejection fraction, the clinical metric pivotal to this initiative, quantifies the proportion of blood ejected from the left ventricle per heartbeat. Normal EF ranges from 55% to 70%, serving as a benchmark for cardiac performance. In patients with HFpEF, the heart’s impaired relaxation compromises ventricular filling without undermining contraction strength, posing diagnostic and therapeutic conundrums. Conversely, HFmrEF reflects a mildly diminished pump function, linking pathophysiology more closely to traditionally studied heart failure phenotypes, but still demanding tailored treatment strategies.

Pharmacological treatment innovations for HFpEF and HFmrEF are burgeoning but remain underutilized. The initiative aims to expedite translation of cutting-edge therapies—including novel agents such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists—into clinical practice by educating providers and fostering rigorous treatment adherence. This effort is anticipated to mitigate morbidity and improve quality of life for millions grappling with these heart failure subtypes.

One of the distinctive features of IMPLEMENT-EF is its emphasis on education and knowledge dissemination. The initiative will deploy an array of professional learning modalities, from interactive eLearning modules and live expert presentations to an innovative podcast series featuring thought leaders in cardiology. These resources are designed to elevate provider competence and confidence, thereby enhancing clinical decision-making and patient management efficacy.

Supporting the educational framework, a dedicated Science Advisory Panel of renowned experts will oversee content development and ensure the integrity and currency of the materials. This panel’s guidance guarantees that frontline clinicians receive the most authoritative and up-to-date information, facilitating the adoption of evidence-based interventions throughout diverse healthcare environments.

Underpinning this ambitious endeavor is collaborative synergy with Bayer, whose support enables the recruitment of 40 hospitals to participate in the program’s inaugural phase. These sites will serve as hubs for knowledge exchange, peer collaboration, and pilot testing of quality improvement models. This experiential learning environment fosters innovation and facilitates scaling of successful interventions to broader healthcare systems, maximizing the initiative’s impact.

The urgency of addressing HFpEF and HFmrEF cannot be overstated. Unlike HFrEF, where decades of research have propelled treatment advances, the lingering knowledge gaps in these subtypes have contributed to stagnant outcomes. IMPLEMENT-EF aims to catalyze progress by infusing data-driven strategies, multidisciplinary cooperation, and targeted education into everyday care delivery, ultimately transforming the prognosis for millions afflicted by these insidious forms of heart failure.

Dr. Mariell Jessup, chief science and medical officer at the AHA, encapsulated the initiative’s vision by emphasizing the necessity of a coordinated, team-based approach. She highlighted how integrating diverse expertise and leveraging real-world data will not only elevate care quality but also forge scalable, replicable models that can be disseminated nationally to benefit broad patient populations.

Similarly, Robert Perkins, vice president of U.S. medical affairs for cardiovascular and renal at Bayer, expressed corporate commitment to advancing translational science in cardiovascular medicine. His remarks underscored the partnership’s shared goal of bridging gaps in evidence and expanding access to innovative, effective treatments for HFpEF and HFmrEF patients.

As this initiative unfolds, the medical community and patients alike are encouraged to stay informed through the AHA’s dedicated portal, HEART.org/IMPLEMENTEF. This resource will provide ongoing updates, insights, and tools emanating from the program’s unfolding progress, fostering transparency and community engagement in this vital quest to reshape heart failure care.

In sum, the American Heart Association’s IMPLEMENT-EF initiative represents a crucial advancement in addressing the unmet needs of heart failure patients with preserved and mildly reduced ejection fractions. By uniting data analytics, multidisciplinary collaboration, and professional education under one ambitious umbrella, the program promises to chart a new course toward improved survival, reduced symptoms, and enhanced quality of life for millions confronting these complex cardiac conditions.

Subject of Research: Heart failure with preserved and mildly reduced ejection fraction (HFpEF and HFmrEF) treatment and care improvement.

Article Title: American Heart Association Launches IMPLEMENT-EF, an Innovative Initiative to Transform Care for HFpEF and HFmrEF Patients.

News Publication Date: September 15, 2025.

Web References:

• https://www.heart.org/en/professional/quality-improvement/IMPLEMENT-EF
• https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-heart-failure
• https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure

References:

1. Savarese G, Stolfo D, Sinagra G, Lund L. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19:100–116.
2. Shah S, Kitzman D, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134(1).
3. Shah K, Xu H, Matsouaka R, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. JACC. 2017 Nov;70(20):2476–2486.
4. Kapelios CJ, Shahim B, Lund LH, Savarese G. Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review. 2023;9:e14.

Keywords: Heart Failure, HFpEF, HFmrEF, Ejection Fraction, Cardiovascular Care, Multidisciplinary Teams, Quality Improvement, Evidence-Based Therapies, Patient Outcomes, American Heart Association, IMPLEMENT-EF, Pharmacological Therapy.